publication . Article . 2019

A Candidate Regulatory Variant at the TREM Gene Cluster Confer Alzheimer’s Disease Risk by Modulating Both Amyloid-β Pathology and Neuronal Degeneration

Mei-Ling Tian; Xiao-Neng Ni; Jie-Qiong Li; Chen-Chen Tan; Xi-Peng Cao; Lan Tan; Lan Tan; for the Alzheimer’s Disease Neuroimaging Initiative;
Open Access English
  • Published: 01 Jul 2019 Journal: Frontiers in Neuroscience (issn: 1662-453X, Copyright policy)
  • Publisher: Frontiers Media S.A.
Background: rs9357347 located at the triggering receptor expressed on myeloid cells (TREM) gene cluster could increase TREM2 and TREM-like transcript 1 (TREML1) brain gene expression, which is considered to play a protective role against Alzheimer’s disease (AD). Objectives: To investigate the role of rs9357347 in AD pathogenesis by exploring the effects of rs9357347 on AD specific biomarkers. Methods: This study analyzed the association of rs9357347 with AD-related cerebrospinal fluid (CSF) and neuroimaging markers from 201 cognitively normal (CN) older adults, 349 elders with mild cognitive impairment (MCI), and 172 elders with AD dementia from the Alzheimer’s...
free text keywords: Alzheimer’s disease, TREM2 gene, TREML1, rs9357347, genetic mechanism, cerebrospinal fluid, Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571, Neuroscience, Original Research, amyloid-β pathology, neuronal degeneration
Related Organizations
Funded by
  • Funder: Canadian Institutes of Health Research (CIHR)
NIH| Alzheimers Disease Neuroimaging Initiative
  • Funder: National Institutes of Health (NIH)
  • Project Code: 1U01AG024904-01
33 references, page 1 of 3

Alzheimer’s Association (2011). 2011 Alzheimer’s disease facts and figures. Alzheimers Dement. 7 208–244. 10.1016/j.jalz.2011.02.004 21414557 [OpenAIRE] [PubMed] [DOI]

Carrasquillo M. M.Allen M.Burgess J. D.Wang X.Strickland S. L.Aryal S. (2017). A candidate regulatory variant at the TREM gene cluster associates with decreased alzheimer’s disease risk and increased TREML1 and TREM2 brain gene expression. Alzheimers Dement. 13 663–673. 10.1016/j.jalz.2016.10.005 27939925 [OpenAIRE] [PubMed] [DOI]

Colonna M. (2003). TREMs in the immune system and beyond. Nat. Rev. Immunol. 3 445–453. 10.1038/nri1106 12776204 [OpenAIRE] [PubMed] [DOI]

Condello C.Yuan P.Grutzendler J. (2018). Microglia-mediated neuroprotection, trem2, and alzheimer’s disease: evidence from optical imaging. Biol. Psychiatry 83 377–387. 10.1016/j.biopsych.2017.10.007 29169609 [OpenAIRE] [PubMed] [DOI]

Dennis J.Selkoe J. H. (2016). The amyloid hypothesis of alzheimer’s disease at 25 years. EMBO Mol. Med. 8 595–608. 10.15252/emmm.201606210 27025652 [OpenAIRE] [PubMed] [DOI]

Derive M.Bouazza Y.Sennoun N.Marchionni S.Quigley L.Washington V. (2012). Soluble TREM-like transcript-1 regulates leukocyte activation and controls microbial sepsis. J. Immunol. 188 5585–5592. 10.4049/jimmunol.1102674 22551551 [OpenAIRE] [PubMed] [DOI]

Fagan A. M.Roe C. M.Xiong C.Mintun M. A.Morris J. C.Holtzman D. M. (2007). Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol. 64 343–349. 10.1001/archneur.64.3.noc60123 17210801 [OpenAIRE] [PubMed] [DOI]

Ford J. W.McVicar D. W. (2009). TREM and TREM-like receptors in inflammation and disease. Curr. Opin. Immunol. 21 38–46. 10.1016/j.coi.2009.01.009 19230638 [OpenAIRE] [PubMed] [DOI]

Hardy J.Selkoe D. J. (2002). The amyloid hypothesis of alzheimer’s disease: progress and problems on the road to therapeutics. Science 297 353–356. 10.1126/science.1072994 12130773 [OpenAIRE] [PubMed] [DOI]

Jack C. R.Jr.Bernstein M. A.Fox N. C.Thompson P.Alexander G.Harvey D. (2008). The alzheimer’s disease neuroimaging initiative (adni): mri methods. J. Magn. Reson. Imaging 27 685–691. 10.1002/jmri.21049 18302232 [OpenAIRE] [PubMed] [DOI]

Jack C. R.Jr.Knopman D. S.Jagust W. J.Shaw L. M.Aisen P. S.Weiner M. W. (2010). Hypothetical model of dynamic biomarkers of the alzheimer’s pathological cascade. Lancet Neurol. 9 119–128. 10.1016/s1474-4422(09)70299-6 20083042 [OpenAIRE] [PubMed] [DOI]

Jagust W. J.Landau S. M.Shaw L. M.Trojanowski J. Q.Koeppe R. A.Reiman E. M. (2009). Relationships between biomarkers in aging and dementia. Neurology 73 1193–1199. 10.1212/WNL.0b013e3181bc010c 19822868 [OpenAIRE] [PubMed] [DOI]

Jay T. R.Miller C. M.Cheng P. J.Graham L. C.Bemiller S.Broihier M. L. (2015). TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in alzheimer’s disease mouse models. J. Exp. Med. 212 287–295. 10.1084/jem.20142322 25732305 [OpenAIRE] [PubMed] [DOI]

Jiang T.Tan L.Zhu X. C.Zhang Q. Q.Cao L.Tan M. S. (2014). Upregulation of TREM2 ameliorates neuropathology and rescues spatial cognitive impairment in a transgenic mouse model of alzheimer’s disease. Neuropsychopharmacology 39 2949–2962. 10.1038/npp.2014.164 25047746 [OpenAIRE] [PubMed] [DOI]

Jiang T.Tan L.Zhu X. C.Zhou J. S.Cao L.Tan M. S. (2015). Silencing of TREM2 exacerbates tau pathology, neurodegenerative changes, and spatial learning deficits in P301S tau transgenic mice. Neurobiol. Aging 36 3176–3186. 10.1016/j.neurobiolaging.2015.08.019 26364736 [OpenAIRE] [PubMed] [DOI]

33 references, page 1 of 3
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue